Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Capital Expenditures: 2020-2023

Historic Capital Expenditures for Candel Therapeutics (CADL) over the last 3 years, with Dec 2023 value amounting to $47,000.

  • Candel Therapeutics' Capital Expenditures fell 82.97% to $47,000 in Q4 2023 from the same period last year, while for Dec 2023 it was $457,000, marking a year-over-year decrease of 64.76%. This contributed to the annual value of $16,000 for FY2024, which is 96.50% down from last year.
  • Per Candel Therapeutics' latest filing, its Capital Expenditures stood at $47,000 for Q4 2023, which was down 54.37% from $103,000 recorded in Q3 2023.
  • In the past 5 years, Candel Therapeutics' Capital Expenditures ranged from a high of $1.9 million in Q1 2021 and a low of -$281,000 during Q3 2021.
  • For the 3-year period, Candel Therapeutics' Capital Expenditures averaged around $299,083, with its median value being $192,000 (2022).
  • As far as peak fluctuations go, Candel Therapeutics' Capital Expenditures tumbled by 138.71% in 2021, and later soared by 261.76% in 2022.
  • Candel Therapeutics' Capital Expenditures (Quarterly) stood at $453,000 in 2020, then increased by 11.26% to $504,000 in 2021, then plummeted by 45.24% to $276,000 in 2022, then crashed by 82.97% to $47,000 in 2023.
  • Its Capital Expenditures was $47,000 in Q4 2023, compared to $103,000 in Q3 2023 and $169,000 in Q2 2023.